Calls for more transparency on cancer drug prices
A GROUP of legal experts on cancer medicines has called for more transparency about the price patients are forced to pay for expensive cancer treatment drugs.
Patients must pay as much as $100,000 for some treatments, meaning the drugs were out of reach of all but the wealthiest patients, the researchers argue in the Medical Journal of Australia.
University of Sydney Centre for Values, Ethics and the Law in Medicine's Narcyz Ghinea and Dr Wendy Lipworth wrote the opinion piece in the journal, published on Monday.
They wrote the cost of many new unsubsidised cancer drugs put "intense" pressure on the government to help fund them for patients to access.
They wrote that a lack of transparency about the price of the medicines, combined with an estimated 225 drugs to enter the market over the next five years, meant the rising number and cost of drugs could impact both the government and patients.